Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is sorafenib plus interferon α2b safe and effective in patients with renal cell carcinoma?

Nature Clinical Practice Urology volume 5, pages 132–133 (2008)Cite this article

boxed-textGollob JA et al. (2007) Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25: 3288–3295

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

    Article  CAS  Google Scholar 

  2. Hudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281

    Article  CAS  Google Scholar 

  3. Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124

    Article  CAS  Google Scholar 

  4. Ryan CW et al. (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25: 3296–3301

    Article  CAS  Google Scholar 

  5. Amato RJ et al. (2007) A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 25 (Suppl 18): 5026

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/Desk R35, Cleveland, OH 44195, USA rinib2@ccf.org

Authors and Affiliations

  1. BI Rini is a Staff Member at the Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.,

    Brian I Rini

Authors
  1. Brian I Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received consulting fees and research funding from the following companies/organizations: Bayer, Genentech, Onyx Pharmaceuticals, Pfizer and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rini, B. Is sorafenib plus interferon α2b safe and effective in patients with renal cell carcinoma?. Nat Rev Urol 5, 132–133 (2008). https://doi.org/10.1038/ncpuro1036

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1036

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing